Prof. Dr. med. Michael Hallek - Curriculum Vitae

Education and professional career

since 2007: Director of the Center of Integrated Oncology, Universities Cologne and Bonn
since 2003: C4-Professor, University of Cologne
1999 - 2003: C3-Professor, University of Munich
1998 - 2005: Head, Clinical Cooperation Group, GSF (Helmholtz-Institute) Munich
1995 - 2003: Senior Consultant, University of Munich
1994 - 2005: Research Group Leader, Gene Center Munich
1990 - 1992: Research Asscociate, Dana Farber Cancer Institute, Harvard Medical School, USA
1985 - 2003: Various residencies and training in pharmacology, internal medicine, hematology and oncology at the Technical University (Rechts der Isar Hospital) and University of Munich (Innenstadt and Grosshadern Hospitals)

Awards, distinctions and professional activities

2017: Arthur Burkhardt-Award
2017: German Cancer Award
2016: Walter-Siegenthaler-Medal in gold
since 2015: Board member and President, German Society of Hematology and Medical Oncology (2016 - 2017)
since 2014: Scientific Board of the German Chamber of Physicians (Bundesärztekammer)
2014 - 2017: Scientific Committee of the American Society of Hematology
2014 - 2015: President, German Society of Internal Medicine
2014: President of the German Cancer Congress
2013: Binet-Rai Medal of the International Workshop on CLL
since 2013: Chairman, Clinical Resarch Unit 286 ‘DNA damage response in CLL’
2013-2016: Senate Commission ‘Grundsatzfragen der Klinischen Forschung’, German Research Council (DFG)
since 2011: Editor-in-Chief ‘Oncology Research and Treatment’
2011: Member of the National Academy of Sciences, Leopoldina
2009 - 2014: Chairman, Collaborative Research Center 832 on ‘tumor microenvironment’
since 2007: Center of excellence in oncology award Center for Integrated Oncology (CIO) Cologne Bonn
since 2000: Scientific Committee (Core Group) International Working Group on CLL (IWCLL)
1999: Artur-Pappenheim-Award, German Society of Hematology and Oncology
since 1996: Founder and Chairman, German CLL Study Group

Selected publications

Fischer K, Al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, Kipps TJ, Weinkove R, Robinson S, Seiler T, Opat S, Owen C, López J, Humphrey K, Humerickhouse R, Tausch E, Frenzel L, Eichhorst B, Wendtner CM, Stilgenbauer S, Langerak AW, van Dongen JJM, Böttcher S, Ritgen M, Goede V, Mobasher M, Hallek M. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 May 11;129(19):2702-2705. doi: 10.1182/blood-2017-01-761973. Epub 2017 Mar 21. PubMed PMID: 28325865.

Nguyen PH, Fedorchenko O, Rosen N, Koch M, Barthel R, Winarski T, Florin A, Wunderlich FT, Reinart N, Hallek M. LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia. Cancer Cell. 2016 Oct 10;30(4):610-622. doi: 10.1016/j.ccell.2016.09.007. PubMed PMID: 27728807.

Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M, Döhner H, Stilgenbauer S. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia. 2017 Mar;31(3):734-738. doi: 10.1038/leu.2016.317. Epub 2016 Nov 2. PubMed PMID: 27909343; PubMed Central PMCID: PMC5332302.

Jerkeman M, Hallek M, Dreyling M, Thieblemont C, Kimby E, Staudt L. Targeting of B-cell receptor signalling in B-cell malignancies. J Intern Med. 2017 Mar 14. doi: 10.1111/joim.12600. [Epub ahead of print] PubMed PMID: 28295729.

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators.; German CLL Study Group (GCLLSG).. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 Jul;17(7):928-42. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20. PubMed PMID: 27216274.

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13. PubMed PMID: 27637985.

Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators.. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 Feb;17(2):200-11. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5. PubMed PMID: 26655421.

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Bottcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Dohner H, Hallek M,* Neuberg D,* Getz G,* Stilgenbauer S* and Wu CJ*. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015, 526, 525-530. *Joint senior authors.

Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, Langerbeins P, von Tresckow J, Engelke A, Maurer C, Kovacs G, Herling M, Tausch E, Kreuzer KA, Eichhorst B, Böttcher S, Seymour JF, Ghia P, Marlton P, Kneba M, Wendtner CM, Döhner H, Stilgenbauer S, Hallek M. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14;127(2):208-15. doi: 10.1182/blood-2015-06-651125. Epub 2015 Oct 20. PubMed PMID: 26486789.

Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J and Hemann MT. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 214, 156, 590-602.

Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Dohner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M and Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014, 370, 1101-1110.

Furman R.R, Sharman JP, Coutre SE, Cheson BD, Pagel, JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps, TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M and O'Brien SM. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014, 370, 997-1007.